Literature DB >> 31022401

Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome.

Magnus Simrén1, Hans Törnblom2, Olafur S Palsson3, Lukas Van Oudenhove4, William E Whitehead3, Jan Tack4.   

Abstract

BACKGROUND & AIMS: Little is known about the link between pathophysiologic factors and symptoms of irritable bowel syndrome (IBS), or whether these factors have cumulative effects on patient-reported outcomes (PROs). We investigated whether pathophysiologic alterations associated with IBS have cumulative or independent effects on PROs.
METHODS: We performed a retrospective analysis of data from 3 cohorts of patients with IBS (n = 407; 74% female; mean age, 36 ± 12 years), based on Rome II or Rome III criteria, seen at a specialized unit for functional gastrointestinal disorders in Sweden from 2002 through 2014. All patients underwent assessments of colonic transit time (radiopaque markers); compliance, allodynia, and hyperalgesia (rectal barostat); anxiety and depression (Hospital Anxiety and Depression scale), as pathophysiologic factors. Dysfunction was defined by available normal values. PROs included IBS symptom severity, somatic symptom severity, and disease-specific quality of life.
RESULTS: Allodynia was observed in 36% of patients, hyperalgesia in 22%, accelerated colonic transit in 18%, delayed transit in 7%, anxiety in 52%, and depression in 24%: each of these factors was associated with severity of at least 1 symptom of IBS. Rectal compliance was not associated with more severe symptoms of IBS. At least 3 pathophysiologic factors were present in 20% of patients, 2 in 30%, 1 in 31%, and none in 18%. With increasing number of pathophysiologic abnormalities, there was a gradual increase in IBS symptom severity (P < .0001) and somatic symptom severity (P < .0001), and a gradual reduction in quality of life (P < .0001).
CONCLUSION: Visceral hypersensitivity, including allodynia and hyperalgesia, abnormal colonic transit, and psychologic factors are all associated with IBS symptoms. These factors have a cumulative effect on gastrointestinal and nongastrointestinal symptoms, as well as on quality of life, in patients with IBS and are therefore relevant treatment targets.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colonic Transit; Patient-Reported Outcomes; Psychologic Distress; Visceral Hypersensitivity

Mesh:

Year:  2019        PMID: 31022401     DOI: 10.1053/j.gastro.2019.04.019

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

Review 1.  Diagnostic Strategy and Tools for Identifying Defecatory Disorders.

Authors:  Adil E Bharucha; Enrique Coss-Adame
Journal:  Gastroenterol Clin North Am       Date:  2022-01-07       Impact factor: 3.806

Review 2.  Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome.

Authors:  Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-09-27       Impact factor: 73.082

Review 3.  Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.

Authors:  Edoardo Savarino; Fabiana Zingone; Brigida Barberio; Giovanni Marasco; Filiz Akyuz; Hale Akpinar; Oana Barboi; Giorgia Bodini; Serhat Bor; Giuseppe Chiarioni; Gheorghe Cristian; Maura Corsetti; Antonio Di Sabatino; Anca Mirela Dimitriu; Vasile Drug; Dan L Dumitrascu; Alexander C Ford; Goran Hauser; Radislav Nakov; Nisha Patel; Daniel Pohl; Cătălin Sfarti; Jordi Serra; Magnus Simrén; Alina Suciu; Jan Tack; Murat Toruner; Julian Walters; Cesare Cremon; Giovanni Barbara
Journal:  United European Gastroenterol J       Date:  2022-06-13       Impact factor: 6.866

4.  Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial.

Authors:  Vladimir T Ivashkin; Anna V Kudryavtseva; George S Krasnov; Yuri M Poluektov; Margarita A Morozova; Oleg S Shifrin; Allan G Beniashvili; Zarina A Mamieva; Alexandra L Kovaleva; Anatoly I Ulyanin; Elizaveta A Trush; Alexander G Erlykin; Elena A Poluektova
Journal:  PLoS One       Date:  2022-06-15       Impact factor: 3.752

Review 5.  Sex as a biological variable in irritable bowel syndrome.

Authors:  Michael Camilleri
Journal:  Neurogastroenterol Motil       Date:  2020-01-13       Impact factor: 3.598

6.  Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome.

Authors:  Gerardo Calderon; Chirag Patel; Michael Camilleri; Toyia James-Stevenson; Matthew Bohm; Robert Siwiec; Nicholas Rogers; John Wo; Carolyn Lockett; Anita Gupta; Huiping Xu; Andrea Shin
Journal:  J Clin Gastroenterol       Date:  2022-03-01       Impact factor: 3.062

Review 7.  Sex- and Gender-Related Differences in Common Functional Gastroenterologic Disorders.

Authors:  Susrutha Puthanmadhom Narayanan; Bradley Anderson; Adil E Bharucha
Journal:  Mayo Clin Proc       Date:  2021-04       Impact factor: 7.616

Review 8.  The enteric nervous system in gastrointestinal disease etiology.

Authors:  Amy Marie Holland; Ana Carina Bon-Frauches; Daniel Keszthelyi; Veerle Melotte; Werend Boesmans
Journal:  Cell Mol Life Sci       Date:  2021-03-26       Impact factor: 9.261

9.  Psychosomatic Disorders in Patients with Gastrointestinal Diseases: Single-Center Cross-Sectional Study of 1186 Inpatients.

Authors:  Lijuan Feng; Zichun Li; Xuerong Gu; Jiahui Jiang; Xiaowei Liu
Journal:  Gastroenterol Res Pract       Date:  2021-05-01       Impact factor: 2.260

Review 10.  The Role of Epigenomic Regulatory Pathways in the Gut-Brain Axis and Visceral Hyperalgesia.

Authors:  Gerald A Higgins; Shaungsong Hong; John W Wiley
Journal:  Cell Mol Neurobiol       Date:  2021-05-31       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.